Inve US ▾
BCBCPC

Balchem (BCPC) Q1 FY26 earnings call: guidance and Q&A

Earnings call· Mar 2026 (Q1 FY26)· Materials· Apr 30, 2026

Source: earnings call transcript

Executive summary

Balchem Q1 FY26 — Record Sales and Adjusted EBITDA Across All Segments

Balchem delivered a strong start to the year with record Q1 FY26 financial results, driven by healthy demand across all segments and successful market penetration of its specialty nutrients. The company continues to leverage its formulation expertise and branded ingredients, particularly VitaCholine, while navigating geopolitical and macroeconomic dynamics, including rising input costs, through strategic pricing and supply chain management. Management remains confident in sustained top and bottom-line growth for the remainder of 2026.

Highlights

5

  • Record first quarter consolidated sales of $271 million, up 8.1% year-over-year.

  • Record quarterly adjusted EBITDA of $74 million, an increase of 12.1%.

  • 27th consecutive quarter of quarterly year-over-year growth in adjusted EBITDA.

  • Gross margin expanded to 37.3% of sales, up 210 basis points year-over-year.

  • Reduced Scope 1 and 2 greenhouse gas emissions by approximately 31% compared to 2020 baseline, surpassing 2030 goal of 25%.

Concerns

2

  • Anticipate modest margin compression in Animal Nutrition & Health due to timing lag between petrochemical-based input cost inflation and pricing adjustments.

  • Effective tax rate increased to 23.3% in Q1 FY26 from 22.7% in Q1 FY25 due to state taxes and discrete items.

Guidance & targets

CategoryTargetConfidence
Consolidated quarterly year-over-year growth
continued growth
high materiality
High
Animal Nutrition & Health segment growth
continue to drive growth
medium materiality
High
Consolidated top and bottom line growth
continued growth
high materiality
High
Effective tax rate
higher in Q2, then lower in H2
low materiality
Medium
Effective tax rate (full year)
23%
low materiality
Medium

Segment performance

SegmentRevenueYoYQoQMargin
Human Nutrition & Health
Driven by growth in both Nutrients and Food Ingredients and Solutions businesses. Favorable mix partially offset by higher manufacturing input costs and operating expenses. Differentiated ingredients and solutions align with consumer shift toward better-for-you nutrition.
Nutrients business growth: very strong, double-digitsFood Ingredients and Solutions businesses growth: lower to mid-single digits
$172 million8.3%—$40 million (GAAP earnings from operations), $43 million (adjusted earnings from operations)
Animal Nutrition & Health
Increase driven by higher sales in both monogastric and ruminant businesses. Improved performance with continued adoption of encapsulated rumen-protected nutrients. U.S. monogastric steady, European monogastric improving post-EU antidumping duties. Facing increases in raw material and freight costs.
Monogastric business growth: higher salesRuminant business growth: higher salesEuropean monogastric business volume improvement: double-digit in Q1
$62 million8.6%—$6 million (GAAP earnings from operations), $6 million (adjusted earnings from operations)
Specialty Products
Driven by healthy growth in Performance Gases. Record quarterly earnings from operations and adjusted earnings from operations. Performance Gases seeing healthy demand in both U.S. and Europe. Plant Nutrition growth primarily from geographic expansion, with significant margin improvement in Q1.
$35 million4.4%—$12 million (GAAP earnings from operations), $13 million (adjusted earnings from operations)

Product announcements

ProductTypeDetails
VitaCholineupdate

Risks & headwinds

Petrochemical-based input cost inflation coming quarters

significant

Mitigation:Leverage robust global supply chain, procurement expertise, strong market positions to raise prices where necessary. Expect modest margin compression due to timing lag.

Supply chain disruptions ongoing

potential

Mitigation:Monitor developments closely and adjust accordingly.

Geopolitical and macroeconomic environment ongoing

dynamic and evolving

Mitigation:Well positioned to effectively manage through.

Increased effective tax rate Q1 FY26, expected higher in Q2

23.3% in Q1 FY26 vs 22.7% in Q1 FY25

Mitigation:Anticipated to modulate lower in H2 FY26 towards a 23% full-year planning rate.

What to watch in Q2 FY26

Consolidated Adjusted EBITDA Growth

next quarter
Current 27th consecutive quarter of year-over-year growth
Target Continued year-over-year growth

Why it matters

Sustained adjusted EBITDA growth is a key indicator of the company's ability to manage costs and pricing in an inflationary environment.

we do expect to deliver continued quarterly year-over-year growth on a consolidated basis over the coming quarters.

Find out whether BCPC delivers this. Inve re-checks your case every morning.

Q&A highlights

What percentage of Human Nutrition & Health sales are branded, and what is the long-term potential?

Branded ingredients, specifically consumer-recognized 'power brands' like VitaCholine, K2VITAL, OptiMSM, and Albion Minerals, make up about 40% to 50% of the Human Nutrition & Health business today. This portion is growing faster than other parts of the business and is expected to become a larger part of the portfolio over time.

“Our branded ingredients, and let's just talk about Human Nutrition & Health, make up about, I would say, 40% to 50% of our Human Nutrition & Health business today.”

asked by Bob Labick · answered by Theodore Harris

2 min read 5 chapters

Detailed narrative

Strategic Initiatives & VitaCholine Research

Balchem highlighted significant progress on strategic initiatives, including a newly published peer-reviewed research study on VitaCholine. The study, published in Nutrients, showed VitaCholine intake significantly enhanced functional connectivity within the working memory network in post-menopausal women, suggesting potential benefits for cognitive health in older adults. This expands on previous research supporting fetal brain development, and the company plans further investment in research and marketing to drive market penetration.

Sustainability Achievements

The company released its 2025 Sustainability Report, demonstrating commitment to its 2030 goals. Balchem successfully reduced Scope 1 and 2 greenhouse gas emissions by approximately 31% compared to its 2020 baseline, surpassing its 25% reduction goal. Water withdrawal was reduced by approximately 16%, showing substantial progress towards its 25% water usage reduction objective, reflecting strong stewardship of employees, customers, shareholders, and communities.

Market Environment & Inflation Management

Balchem continues to see healthy demand across most end markets, particularly Human Nutrition & Health, benefiting from better-for-you trends. The company is entering a period of significant petrochemical-based inflation, primarily impacting the Animal Nutrition & Health segment, and potential supply chain disruptions from geopolitical events. Management plans to leverage its robust global supply chain, procurement expertise, and strong market positions to raise prices where necessary, expecting modest margin compression due to timing lags between cost increases and pricing adjustments.

International Growth Focus

Geographic expansion remains a primary strategic focus for Balchem, with the company actively hiring personnel in various international regions around the world. This investment in sales and marketing is contributing to higher growth rates in most international locations compared to the U.S., driven by a lower base. The company is building out the necessary infrastructure to support this strategic initiative and is seeing positive results from these efforts.

Animal Nutrition & Health Recovery

The Animal Nutrition & Health segment showed improved performance, with double-digit volume improvement and improved pricing in the European monogastric business following EU antidumping duties. The U.S. monogastric business remained steady, and the ruminant business continued to see adoption of encapsulated rumen-protected nutrients. Management is closely monitoring geopolitical impacts on input costs and freight for this segment, but remains confident in its ability to drive continued growth over time.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.